Glioblastoma: all 1,951 studies
Page 14 of 20. Open to participants first (457), then studies with results posted, then the rest; newest registration first within each.
- Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBMTerminatedNCT03283631Phase 1
- Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)CompletedNCT03277638Phase 1/2
- Nativis Voyager for Newly Diagnosed GBMCompletedNCT03276286Not applicable
- Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of GlioblastomaWithdrawnNCT03275558Phase 1
- TTFields In GErmany in Routine Clinical CareStatus unknownNCT03258021
- Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV GliomaActive, not recruitingNCT03251027Not applicable
- Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for GlioblastomaTerminatedNCT03246113Phase 1
- Mind-Body Intervention in Glioma CouplesActive, not recruitingNCT03244995Not applicable
- Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory GlioblastomaCompletedNCT03243851Phase 2
- International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)Status unknownNCT03243461Phase 3
- Glycemic Impact on Glioblastoma OutcomesWithdrawnNCT03235934
- A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.Active, not recruitingNCT03233152Phase 1/2
- NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed GlioblastomaCompletedNCT03232424Phase 1
- HMPL-813 in Treating Patients With GlioblastomaStatus unknownNCT03231501Phase 1
- Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.Status unknownNCT03225963
- Simultaneous Integrated Boost in Malignant Glioma Patients Treated With ChemoradiationStatus unknownNCT03225300Not applicable
- Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat GlioblastomaActive, not recruitingNCT03223103Phase 1
- Hypofractionated Radiation Therapy for GlioblastomaStatus unknownNCT03212235Phase 2
- NovoTTF Treatment Signatures in Glioblastoma Patients at AutopsyCompletedNCT03194971
- Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in GlioblastomasActive, not recruitingNCT03181477Not applicable
- LITT Palliative Treatment for Patients With Malignant GliomasWithdrawnNCT03176160
- NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2
- CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With GlioblastomaStatus unknownNCT03152708
- A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2Active, not recruitingNCT03152318Phase 1
- Bioavailability of Disulfiram and Metformin in GlioblastomasTerminatedNCT03151772Early Phase 1
- VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBMTerminatedNCT03149575Phase 3
- Expanded Access to ABT-414No longer availableNCT03123952
- DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent GlioblastomaActive, not recruitingNCT03115333Not applicable
- Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.TerminatedNCT03115138Not applicable
- Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain CancerTerminatedNCT03107780Phase 1
- Ketogenic Diets as an Adjuvant Therapy in GlioblastomaCompletedNCT03075514Not applicable
- Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed GlioblastomaSuspendedNCT03055208Not applicable
- Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT ExpressionCompletedNCT03050736Phase 2
- INtraoperative photoDYnamic Therapy of GliOblastomaCompletedNCT03048240Not applicable
- Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent GlioblastomaCompletedNCT03033524Phase 2
- A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma MultiformeStatus unknownNCT03025893Phase 2/3
- BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With BevacizumabCompletedNCT03020602Phase 1
- Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaWithdrawnNCT03014804Phase 2
- Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)CompletedNCT02997423
- A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Active, not recruitingNCT02974738Phase 1
- Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain MetastasesTerminatedNCT02967380Not applicable
- uPAR-PET/MRI in Glioblastoma MultiformeStatus unknownNCT02945826Phase 2
- Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot StudyStatus unknownNCT02939378Phase 1/2
- Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma MultiformeStatus unknownNCT02937844Phase 1
- Ribociclib (LEE011) in Preoperative Glioma and Meningioma PatientsActive, not recruitingNCT02933736Early Phase 1
- Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With GlioblastomaStatus unknownNCT02928575Phase 2
- Regorafenib in Relapsed GlioblastomaCompletedNCT02926222Phase 2
- Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With GlioblastomaWithdrawnNCT02919332
- IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With GlioblastomaStatus unknownNCT02910804Early Phase 1
- Discerning Pseudoprogression vs True Tumor Growth in GBMsTerminatedNCT02905643
- Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine ModelStatus unknownNCT02904525Not applicable
- Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain CancerCompletedNCT02903069Phase 1
- FDG PET/CT in Monitoring Very Early Therapy Response in Patients With GlioblastomaCompletedNCT02902757Not applicable
- MRI Detection of Microbleeds in Glioma PatientsCompletedNCT02899663
- Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional StatusCompletedNCT02898012Phase 2
- Enhancing Optune Therapy With Targeted CraniectomyCompletedNCT02893137Phase 1
- Glioblastoma Platelet Activation StudyCompletedNCT02887417
- FDG PET Imaging in Diagnosing Patients With GlioblastomaCompletedNCT02885272Early Phase 1
- Feasibility Study on LITT for Newly Diagnosed GlioblastomaTerminatedNCT02880410Phase 1
- Efficacy and Safety of G-202 in PSMA-Positive GlioblastomaWithdrawnNCT02876003Phase 2
- RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic GliomasCompletedNCT02871843Phase 1
- A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM PatientsCompletedNCT02869243Phase 1
- A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent GlioblastomaCompletedNCT02866747Phase 1/2
- A Study of CAN008 for Newly Diagnosed Glioblastoma MultiformeCompletedNCT02853565Phase 1
- Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma PatientsTerminatedNCT02850744Phase 2
- Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma MultiformeStatus unknownNCT02844062Phase 1
- Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRICompletedNCT02843230
- Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent GlioblastomaTerminatedNCT02841332Not applicable
- Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade GliomaTerminatedNCT02833701Phase 1
- A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent GlioblastomaCompletedNCT02820584Phase 1
- Validation of the Role of Levetiracetam for Newly Diagnosed GBM PatientsStatus unknownNCT02815410Phase 2
- Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)CompletedNCT02808364Phase 1
- Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With GlioblastomaCompletedNCT02799238Phase 2
- Combination Adenovirus + Pembrolizumab to Trigger Immune Virus EffectsCompletedNCT02798406Phase 2
- Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma GliomasStatus unknownNCT02795364Not applicable
- Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBMActive, not recruitingNCT02780024Phase 2
- Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)Status unknownNCT02772094Phase 2
- A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent GlioblastomaCompletedNCT02770378Phase 1/2
- Advanced Perfusion MRI of Treatment Response and Progression in GlioblastomaTerminatedNCT02769806
- Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent GlioblastomaCompletedNCT02768389Early Phase 1
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBMCompletedNCT02766699Phase 1
- Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase IIICompletedNCT02761070Phase 3
- Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine GliomaTerminatedNCT02758366Phase 2
- A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent GlioblastomaWithdrawnNCT02754362Phase 2
- Determination of Immune Phenotype in Glioblastoma PatientsCompletedNCT02751138
- A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade GliomasCompletedNCT02750891Phase 1/2
- Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced GlioblastomaCompletedNCT02728349Phase 1
- Using Genomic Analysis to Guide Individual Treatment in GlioblastomaCompletedNCT02725684
- Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) VaccineTerminatedNCT02722512Phase 1
- VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a GlioblastomaCompletedNCT02718443Phase 1
- Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent SettingCompletedNCT02717962Phase 2
- Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent GlioblastomaStatus unknownNCT02715297Phase 2
- Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)CompletedNCT02709616Phase 1
- Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaCompletedNCT02709226Phase 1
- Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaActive, not recruitingNCT02704858Phase 1/2
- Bevacizumab and Nimustine in Patients With Recurrent High Grade GliomaCompletedNCT02698280Phase 2
- Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02685605Phase 3
- Disulfiram in Recurrent GlioblastomaCompletedNCT02678975Phase 2/3
- Capecitabine + Bevacizumab in Patients With Recurrent GlioblastomaCompletedNCT02669173Phase 1
- Radiomics for Prediction of Survival in GBMCompletedNCT02666066